📊 SIBN Key Takeaways
Is SI-BONE, Inc. (SIBN) a Good Investment?
SI-BONE demonstrates strong medical device fundamentals with 20.2% revenue growth and exceptional 79.6% gross margins, indicating robust product economics. Profitability is rapidly improving (net loss shrinking 38.8% YoY) with adequate balance sheet strength (0.20x leverage, 42.2M cash) to sustain the path to profitability, though negative operating cash flow and continued losses present near-term execution risk.
Why Buy SI-BONE, Inc. Stock? SIBN Key Strengths
- Strong revenue growth of 20.2% YoY in specialized surgical device market
- Exceptional gross margin of 79.6% indicating strong pricing power and cost structure
- Rapidly improving profitability with net losses declining 38.8% YoY and losses narrowing toward breakeven
- Strong balance sheet with low debt-to-equity of 0.20x and exceptional liquidity (8.55x current ratio)
- Substantial cash position of 42.2M providing runway for growth investments
SIBN Stock Risks: SI-BONE, Inc. Investment Risks
- Company remains unprofitable at operating (-11.1% margin) and net (-9.4% margin) income levels with no positive earnings
- Negative operating cash flow (-675K) and free cash flow (-9.1M) indicate ongoing cash burn despite revenue growth
- Inability to cover interest expenses with operations (-25.3x coverage) despite manageable debt levels
- Cash burn rate requires continued capital discipline; limited runway if trajectory stalls
- Medical device sector execution risk: must achieve profitability while maintaining growth rates and margins
Key Metrics to Watch
- Operating cash flow inflection point to positive territory
- Operating margin improvement toward breakeven and profitability
- Operating expense control and sales/marketing efficiency relative to revenue growth
- Gross margin sustainability above 75% as company scales
- Quarterly cash position and burn rate to confirm path to profitability within 18-24 months
SI-BONE, Inc. (SIBN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.55x current ratio provides a solid financial cushion.
SIBN Profit Margin, ROE & Profitability Analysis
SIBN vs Healthcare Sector: How SI-BONE, Inc. Compares
How SI-BONE, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is SI-BONE, Inc. Stock Overvalued? SIBN Valuation Analysis 2026
Based on fundamental analysis, SI-BONE, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
SI-BONE, Inc. Balance Sheet: SIBN Debt, Cash & Liquidity
SIBN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: SI-BONE, Inc.'s revenue has grown significantly by 123% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.13 indicates the company is currently unprofitable.
SIBN Revenue Growth, EPS Growth & YoY Performance
SIBN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $40.3M | -$4.6M | $-0.11 |
| Q2 2025 | $40.0M | -$6.2M | $-0.14 |
| Q1 2025 | $37.9M | -$6.5M | $-0.15 |
| Q3 2024 | $34.0M | -$6.6M | $-0.16 |
| Q2 2024 | $33.3M | -$8.9M | $-0.22 |
| Q1 2024 | $32.7M | -$10.9M | $-0.27 |
| Q3 2023 | $26.4M | -$10.0M | $-0.25 |
| Q2 2023 | $25.6M | -$11.1M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
SI-BONE, Inc. Dividends, Buybacks & Capital Allocation
SIBN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for SI-BONE, Inc. (CIK: 0001459839)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SIBN
What is the AI rating for SIBN?
SI-BONE, Inc. (SIBN) has an AI rating of BUY with 67% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SIBN's key strengths?
Claude: Strong revenue growth of 20.2% YoY in specialized surgical device market. Exceptional gross margin of 79.6% indicating strong pricing power and cost structure.
What are the risks of investing in SIBN?
Claude: Company remains unprofitable at operating (-11.1% margin) and net (-9.4% margin) income levels with no positive earnings. Negative operating cash flow (-675K) and free cash flow (-9.1M) indicate ongoing cash burn despite revenue growth.
What is SIBN's revenue and growth?
SI-BONE, Inc. reported revenue of $200.9M.
Does SIBN pay dividends?
SI-BONE, Inc. does not currently pay dividends.
Where can I find SIBN SEC filings?
Official SEC filings for SI-BONE, Inc. (CIK: 0001459839) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SIBN's EPS?
SI-BONE, Inc. has a diluted EPS of $-0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SIBN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, SI-BONE, Inc. has a BUY rating with 67% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is SIBN stock overvalued or undervalued?
Valuation metrics for SIBN: ROE of -10.6% (sector avg: 15%), net margin of -9.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SIBN stock in 2026?
Our dual AI analysis gives SI-BONE, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SIBN's free cash flow?
SI-BONE, Inc.'s operating cash flow is $-675.0K, with capital expenditures of $8.4M. FCF margin is -4.5%.
How does SIBN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9.4% (avg: 12%), ROE -10.6% (avg: 15%), current ratio 8.55 (avg: 2).